Ketoconazole

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, October 19, 2023

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.

Key Points: 
  • STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.
  • Poster presentation details are below and will be available on the Presentation and Publication page on the Calliditas' corporate website following the meeting.
  • It has not been established whether TARPEYO slows kidney function decline in patients with IgAN.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, October 19, 2023

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.

Key Points: 
  • STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.
  • Poster presentation details are below and will be available on the Presentation and Publication page on the Calliditas' corporate website following the meeting.
  • It has not been established whether TARPEYO slows kidney function decline in patients with IgAN.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Public advisory - Unauthorized health products seized from Yang Sheng Health Food and G&R Ginseng Trading stores in Richmond, B.C., may pose serious health risks

Retrieved on: 
Friday, August 11, 2023

Health Canada is warning consumers about unauthorized health products it seized from Yang Sheng Health Food Ltd. and two G&R Ginseng Trading Ltd. locations in Richmond, B.C.

Key Points: 
  • Health Canada is warning consumers about unauthorized health products it seized from Yang Sheng Health Food Ltd. and two G&R Ginseng Trading Ltd. locations in Richmond, B.C.
  • These products are labelled to contain prescription drugs and may pose serious health risks.
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • Consult a health care professional if you have used any of these products and have health concerns.

What is dandruff? How do I get rid of it? Why does it keep coming back?

Retrieved on: 
Thursday, July 27, 2023

Up to half of all adults have had this scalp condition at one point, so you’ll no doubt know about these skin flakes and the itchiness.

Key Points: 
  • Up to half of all adults have had this scalp condition at one point, so you’ll no doubt know about these skin flakes and the itchiness.
  • It can affect many aspects of people’s lives, such as how they socialise, how they style their hair, and what clothes they wear.
  • We don’t know for sure whether our ancestors were as bothered by it as much as we are today.

What causes dandruff?

    • The yeast feeds on sebum, the natural moisturiser secreted by your sebaceous glands to stop your skin drying out.
    • These glands are attached to every hair follicle and the hair provides a dark, sheltered micro-environment ideal for the yeast to flourish.
    • This causes the cells to cluster together, appearing as white flakes.

Why do I have dandruff?

    • This depends on a range of factors.
    • Other factors include your immunity, and external factors, such as which hair-care products you use.

How do I get rid of dandruff?

    • The shampoos most commonly contain the anti-fungal agent zinc pyrithione (ZnPT for short).
    • Other common anti-fungals in shampoos include selenium sulfide, ketoconazole and coal tar.
    • You can also treat dandruff with scalp masks and scrubs that help restore the scalp barrier, by reducing inflammation and irritation.

Why does my dandruff come back?

    • Our research focussing on zinc pyrithione-based products showed these shampoos reached the skin surface.
    • We found the zinc pythione seemed to target the top of the follicles rather than deep into the follicles.
    • Your shampoo’s active ingredient may not reach the yeast that causes your dandruff.

What about future treatments?

    • These might target how the yeast grows in a different way to current active ingredients.
    • These include pre-biotics (supplements or food for skin flora) or pro-biotics (products that contain skin flora).

In a nutshell

    • Hopefully, we can develop improved shampoos that better deliver the active ingredient to where it’s needed.
    • These are important for our immunity, including preventing more disease-causing microbes (pathogens) from moving in.
    • They also help the skin produce antimicrobial peptides (short proteins) that protect us from pathogens.

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

Retrieved on: 
Friday, May 5, 2023

STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.

Key Points: 
  • STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.
  • "We are delighted that these data presentations have been selected for the upcoming ERA Congress 2023 and extend our congratulations to all the authors involved.
  • Poster presentation details are below and will be available on the Investor page on the Calliditas' corporate website following the meeting.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

Retrieved on: 
Friday, May 5, 2023

STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.

Key Points: 
  • STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.
  • "We are delighted that these data presentations have been selected for the upcoming ERA Congress 2023 and extend our congratulations to all the authors involved.
  • Poster presentation details are below and will be available on the Investor page on the Calliditas' corporate website following the meeting.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.